Triple
T184502
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | European Medicines Agency |
E3950
|
entity |
| Predicate | hasCommittee |
P1396
|
FINISHED |
| Object |
Pharmacovigilance Risk Assessment Committee
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of medicines and managing pharmacovigilance activities within the European Union.
|
E3950
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pharmacovigilance Risk Assessment Committee | Statement: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee Context triple: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
-
A.
European Directorate for the Quality of Medicines & HealthCare
The European Directorate for the Quality of Medicines & HealthCare is a Council of Europe body responsible for developing quality standards and guidance to ensure the safety and efficacy of medicines and improve healthcare across member states.
-
B.
European Medicines Agency
The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
-
C.
UK Medicines and Healthcare products Regulatory Agency
The UK Medicines and Healthcare products Regulatory Agency is the United Kingdom’s national authority responsible for regulating medicines, medical devices, and healthcare products to ensure their safety, quality, and effectiveness.
-
D.
Facilitation Committee
The Facilitation Committee is a specialized body within the International Maritime Organization responsible for simplifying and harmonizing international maritime trade procedures and documentation.
-
E.
WHO Emergency Committee
The WHO Emergency Committee is a group of international public health experts convened by the World Health Organization to assess serious disease outbreaks and advise on whether they constitute a global health emergency.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Pharmacovigilance Risk Assessment Committee Triple: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
Generated description
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of medicines and managing pharmacovigilance activities within the European Union.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee Target entity description: The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of medicines and managing pharmacovigilance activities within the European Union.
-
A.
European Directorate for the Quality of Medicines & HealthCare
The European Directorate for the Quality of Medicines & HealthCare is a Council of Europe body responsible for developing quality standards and guidance to ensure the safety and efficacy of medicines and improve healthcare across member states.
-
B.
European Medicines Agency
chosen
The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
-
C.
UK Medicines and Healthcare products Regulatory Agency
The UK Medicines and Healthcare products Regulatory Agency is the United Kingdom’s national authority responsible for regulating medicines, medical devices, and healthcare products to ensure their safety, quality, and effectiveness.
-
D.
Facilitation Committee
The Facilitation Committee is a specialized body within the International Maritime Organization responsible for simplifying and harmonizing international maritime trade procedures and documentation.
-
E.
WHO Emergency Committee
The WHO Emergency Committee is a group of international public health experts convened by the World Health Organization to assess serious disease outbreaks and advise on whether they constitute a global health emergency.
- F. None of above.
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a25497e2f08190a040f8c6e1842643 |
completed | Feb. 28, 2026, 2:36 a.m. |
| NER | Named-entity recognition | batch_69a25926be9c8190a4cfce66f57589d1 |
completed | Feb. 28, 2026, 2:55 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69a2fd0577588190a91be504e3c9f0ab |
completed | Feb. 28, 2026, 2:34 p.m. |
| NEDg | Description generation | batch_69a2fe0b1c148190854569c3f6e03a91 |
completed | Feb. 28, 2026, 2:39 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69a2fe7676488190b0d126a7d3d75b5f |
completed | Feb. 28, 2026, 2:40 p.m. |
Created at: Feb. 28, 2026, 2:40 a.m.